MCID: MSC190
MIFTS: 37

Muscular Disease

Categories: Muscle diseases, Neuronal diseases

Aliases & Classifications for Muscular Disease

MalaCards integrated aliases for Muscular Disease:

Name: Muscular Disease 12 15 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0080000

Summaries for Muscular Disease

Disease Ontology : 12 A musculoskeletal system disease that affects the muscles.

MalaCards based summary : Muscular Disease is related to myopathy and muscular dystrophy. An important gene associated with Muscular Disease is POMGNT2 (Protein O-Linked Mannose N-Acetylglucosaminyltransferase 2 (Beta 1,4-)), and among its related pathways/superpathways is Cell Differentiation - Index. The drugs Infliximab and Dermatologic Agents have been mentioned in the context of this disorder. Affiliated tissues include brain, skeletal muscle and bone.

Wikipedia : 74 In medicine, myopathy is a disease of the muscle in which the muscle fibers do not function properly.... more...

Related Diseases for Muscular Disease

Diseases related to Muscular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 349, show less)
# Related Disease Score Top Affiliating Genes
1 myopathy 33.9 UTRN SERPINA3 RYR1 MYOG MYOD1 EPRS1
2 muscular dystrophy 31.7 UTRN RYR1 POMGNT2 MYOD1 DMD B3GNT2
3 neuromuscular disease 31.3 UTRN SERPINA3 RYR1 MYOG MYOD1 H2AC18
4 myositis 31.3 SERPINA3 RYR1 ICOSLG DMD
5 muscular dystrophy, duchenne type 31.3 UTRN MYOD1 MIR675 MIR221 DMD
6 muscular dystrophy, becker type 31.0 UTRN MYOD1 MIR221 DMD B3GNT2
7 collagen disease 30.8 SERPINA3 H2AC18 CCR6
8 amyotrophic lateral sclerosis 1 30.8 UTRN U2AF1 SERPINA3 MIR9-1 MIR142 H2AC18
9 muscular dystrophy, congenital, lmna-related 30.8 MYOG MYOD1 DMD B3GNT2
10 inclusion body myositis 30.7 SERPINA3 MIR221 ICOSLG
11 muscular dystrophy-dystroglycanopathy , type a, 4 30.7 RNU4ATAC POMGNT2 DMD B3GNT2
12 myopathy, congenital 30.7 RYR1 MYOG DMD
13 systemic scleroderma 30.6 MIR142 ICOSLG H2AC18 CCR6
14 facioscapulohumeral muscular dystrophy 1 30.6 MYOG MYOD1 MIR221 DMD
15 histiocytosis 30.6 U2AF1 SERPINA3 CCR6
16 distal arthrogryposis 30.5 SERPINA3 RYR1 MYOD1 H2AC18
17 atrophic muscular disease 12.1
18 muscular dystrophy-dystroglycanopathy 10.9 POMGNT2 DMD B3GNT2
19 congenital muscular dystrophy-dystroglycanopathy type a 10.9 RNU4ATAC POMGNT2 DMD B3GNT2
20 cerebral degeneration 10.9 SERPINA3 H2AC18 EPRS1 CRYAA CCR6 B3GNT2
21 bacterial infectious disease 10.9 SERPINA3 ICOSLG H2AC18 CCR6
22 blood coagulation disease 10.9 U2AF1 SERPINA3 ICOSLG H2AC18 CCR6
23 mast cell neoplasm 10.9 U2AF1 SERPINA3 ICOSLG H2AC18
24 prion disease 10.9 SERPINA3 MIR9-1 MIR142 H2AC18 CRYAA
25 cervix carcinoma 10.9 U2AF1 SERPINA3 MIR199A1 H2AC18 CCR6
26 hypersensitivity reaction type iv disease 10.9 SERPINA3 ICOSLG H2AC18 CCR6
27 congenital nervous system abnormality 10.9 RNU4ATAC MIR9-1 H2AC18 EPRS1 CRYAA B3GNT2
28 ovary epithelial cancer 10.9 U2AF1 SERPINA3 MIR9-1 MIR199A1 ICOSLG H2AC18
29 oropharynx cancer 10.9 SERPINA3 MIR9-1 MIR199A1 H2AC18
30 malignant ovarian surface epithelial-stromal neoplasm 10.9 U2AF1 SERPINA3 MIR9-1 MIR199A1 ICOSLG H2AC18
31 parasitic protozoa infectious disease 10.9 SERPINA3 ICOSLG H2AC18 EPRS1 CCR6
32 autoimmune disease of central nervous system 10.9 U2AF1 SERPINA3 MIR9-1 MIR142 ICOSLG H2AC18
33 salivary gland disease 10.9 SERPINA3 ICOSLG H2AC18 CCR6
34 physical disorder 10.9 RNU4ATAC MIR9-1 H2AC18 EPRS1 CRYAA B3GNT2
35 intestinal benign neoplasm 10.9 SERPINA3 MIR199A1 MIR142 H2AC18 CCR6
36 parasitic helminthiasis infectious disease 10.9 SERPINA3 ICOSLG H2AC18 CCR6
37 extrinsic cardiomyopathy 10.9 SERPINA3 MIR199A1 MIR142 ICOSLG H2AC18 CCR6
38 commensal bacterial infectious disease 10.9 SERPINA3 ICOSLG H2AC18 CCR6
39 bile duct adenocarcinoma 10.9 SERPINA3 MIR9-1 MIR199A1 MIR142 H2AC18 CCR6
40 acute cystitis 10.9 SERPINA3 H2AC18 EPRS1 CCR6
41 bone resorption disease 10.9 SERPINA3 MIR199A1 MIR142 H2AC18 CCR6
42 autoimmune disease of musculoskeletal system 10.9 SERPINA3 MIR142 ICOSLG H2AC18 CCR6
43 uveal disease 10.9 U2AF1 SERPINA3 MIR9-1 MIR199A1 MIR142 ICOSLG
44 gastrointestinal system benign neoplasm 10.9 SERPINA3 MIR199A1 MIR142 H2AC18 CCR6
45 amino acid metabolic disorder 10.9 SERPINA3 H2AC18 EPRS1 CRYAA
46 chromosomal disease 10.9 U2AF1 SERPINA3 MIR9-1 MIR142 H2AC18 EPRS1
47 specific developmental disorder 10.9 U2AF1 SERPINA3 RNU4ATAC MIR9-1 H2AC18 EPRS1
48 bronchial disease 10.9 SERPINA3 MIR142 ICOSLG H2AC18 CCR6
49 pharynx cancer 10.9 SERPINA3 MIR9-1 MIR199A1 MIR142 H2AC18 CCR6
50 cranial nerve disease 10.9 SERPINA3 ICOSLG CRYAA CCR6
51 bile duct disease 10.9 SERPINA3 MIR9-1 MIR199A1 MIR142 ICOSLG H2AC18
52 primary bacterial infectious disease 10.9 SERPINA3 MIR142 ICOSLG H2AC18 CCR6
53 eye degenerative disease 10.9 U2AF1 SERPINA3 RNU4ATAC ICOSLG H2AC18 EPRS1
54 biliary tract disease 10.9 SERPINA3 MIR9-1 MIR199A1 MIR142 ICOSLG H2AC18
55 bone remodeling disease 10.9 SERPINA3 MIR199A1 MIR142 H2AC18 CCR6
56 retinal cancer 10.9 MIR9-1 MIR675 MIR199A1 MIR142 H2AC18 CRYAA
57 leukocyte disease 10.9 U2AF1 SERPINA3 MIR199A1 MIR142 ICOSLG H2AC18
58 pleural disease 10.9 SERPINA3 MIR199A1 H2AC18 CCR6
59 undifferentiated embryonal sarcoma of the liver 10.9 SERPINA3 MYOG MYOD1
60 embryonal sarcoma 10.9 SERPINA3 MYOG MYOD1
61 testicular disease 10.9 SERPINA3 MIR199A1 H2AC18 CCR6
62 infratentorial cancer 10.9 U2AF1 MIR9-1 MIR199A1 MIR142 H2AC18
63 demyelinating disease 10.9 U2AF1 SERPINA3 MIR9-1 MIR142 ICOSLG H2AC18
64 autoimmune disease of endocrine system 10.9 MIR142 ICOSLG H2AC18 CCR6
65 gas gangrene 10.9 SERPINA3 MYOG MYOD1 DMD
66 inherited metabolic disorder 10.9 SERPINA3 MIR9-1 MIR199A1 MIR142 H2AC18 EPRS1
67 bone sarcoma 10.9 SERPINA3 MIR9-1 MIR199A1 MIR142 H2AC18
68 corneal disease 10.9 SERPINA3 H2AC18 CRYAA CCR6
69 bacterial pneumonia 10.9 SERPINA3 ICOSLG H2AC18 CCR6
70 spinal cord disease 10.9 MIR142 ICOSLG H2AC18 CCR6
71 autonomic nervous system neoplasm 10.9 U2AF1 SERPINA3 MIR9-1 MIR199A1 MIR142 ICOSLG
72 upper respiratory tract disease 10.9 SERPINA3 MIR9-1 MIR199A1 MIR142 ICOSLG H2AC18
73 pre-malignant neoplasm 10.9 SERPINA3 MIR142 H2AC18 CCR6
74 mature b-cell neoplasm 10.9 U2AF1 MIR9-1 MIR199A1 MIR142 ICOSLG H2AC18
75 peripheral nervous system neoplasm 10.9 U2AF1 SERPINA3 MIR9-1 MIR199A1 MIR142 ICOSLG
76 chediak-higashi syndrome 10.9 SERPINA3 ICOSLG H2AC18 CCR6
77 nasopharyngeal disease 10.9 MIR9-1 MIR199A1 MIR142 ICOSLG H2AC18 CCR6
78 skin melanoma 10.9 U2AF1 MIR199A1 ICOSLG H2AC18 CCR6
79 lipid storage disease 10.9 SERPINA3 MIR199A1 MIR142 H2AC18 CCR6
80 bone inflammation disease 10.9 SERPINA3 MIR675 MIR199A1 MIR142 ICOSLG H2AC18
81 endocrine organ benign neoplasm 10.9 SERPINA3 MIR221 MIR199A1 MIR142 H2AC18
82 central nervous system cancer 10.9 U2AF1 SERPINA3 MIR9-1 MIR199A1 MIR142 ICOSLG
83 ocular cancer 10.9 U2AF1 MIR9-1 MIR675 MIR199A1 MIR142 H2AC18
84 intrinsic cardiomyopathy 10.9 MIR199A1 MIR142 ICOSLG H2AC18 EPRS1 DMD
85 connective tissue cancer 10.9 U2AF1 SERPINA3 MIR9-1 MIR199A1 MIR142 ICOSLG
86 cervix disease 10.9 MIR9-1 MIR199A1 MIR142 ICOSLG H2AC18 CCR6
87 bone marrow cancer 10.9 U2AF1 MIR9-1 MIR199A1 MIR142 ICOSLG H2AC18
88 thyroid gland disease 10.9 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142 ICOSLG
89 autoimmune disease of eyes, ear, nose and throat 10.9 ICOSLG CRYAA CCR6
90 cell type benign neoplasm 10.9 SERPINA3 MIR221 MIR199A1 MIR142 H2AC18 CCR6
91 autoimmune disease of urogenital tract 10.9 ICOSLG H2AC18 CCR6
92 melanoma, uveal 10.9 U2AF1 MIR9-1 MIR199A1 MIR142 H2AC18 CRYAA
93 esophageal disease 10.9 MIR675 MIR199A1 MIR142 ICOSLG H2AC18 CCR6
94 emery-dreifuss muscular dystrophy 7, autosomal dominant 10.9
95 muscular dystrophy-dystroglycanopathy , type c, 8 10.9
96 diaphragm disease 10.9
97 skeletal muscle cancer 10.9 SERPINA3 MYOG MYOD1 MIR675 MIR199A1 H2AC18
98 hypersensitivity reaction type iii disease 10.9 SERPINA3 ICOSLG CCR6
99 malignant mesenchymoma 10.9 SERPINA3 MYOG MYOD1
100 heart conduction disease 10.9 SERPINA3 MIR199A1 MIR142 H2AC18
101 isolated growth hormone deficiency 10.9 U2AF1 RNU4ATAC H2AC18
102 pervasive developmental disorder 10.9 U2AF1 SERPINA3 MIR9-1 MIR142 H2AC18 EPRS1
103 placenta disease 10.9 SERPINA3 MIR675 MIR199A1 H2AC18
104 integumentary system disease 10.9 U2AF1 SERPINA3 MIR9-1 MIR199A1 MIR142 ICOSLG
105 oral cavity cancer 10.9 MIR9-1 MIR199A1 MIR142 H2AC18 CCR6
106 bone cancer 10.9 SERPINA3 MIR9-1 MIR199A1 MIR142 H2AC18
107 overnutrition 10.8 SERPINA3 MIR221 MIR199A1 MIR142 ICOSLG H2AC18
108 substance abuse 10.8 SERPINA3 MIR199A1 H2AC18 CCR6
109 spinal disease 10.8 U2AF1 SERPINA3 RNU4ATAC MIR9-1 MIR199A1 MIR142
110 pulmonary disease, chronic obstructive 10.8 SERPINA3 MIR199A1 MIR142 ICOSLG H2AC18 EPRS1
111 mouth disease 10.8 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142 ICOSLG
112 isolated growth hormone deficiency, type ia 10.8 U2AF1 RNU4ATAC H2AC18 CRYAA
113 hair disease 10.8 RNU4ATAC ICOSLG H2AC18 CCR6
114 autoimmune disease of cardiovascular system 10.8 ICOSLG H2AC18 CCR6
115 heart valve disease 10.8 SERPINA3 MIR675 MIR199A1 H2AC18
116 heart septal defect 10.8 U2AF1 RNU4ATAC MIR199A1 H2AC18
117 laryngeal disease 10.8 MIR9-1 MIR142 H2AC18 CCR6
118 bladder disease 10.8 U2AF1 MIR9-1 MIR675 MIR199A1 MIR142 ICOSLG
119 blood platelet disease 10.8 U2AF1 ICOSLG H2AC18 CCR6
120 autoimmune disease of blood 10.8 SERPINA3 ICOSLG CCR6
121 lacrimal apparatus disease 10.8 ICOSLG CRYAA CCR6
122 male reproductive organ cancer 10.8 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142 ICOSLG
123 germ cell cancer 10.8 SERPINA3 MIR9-1 MIR199A1 H2AC18
124 optic nerve disease 10.8 SERPINA3 ICOSLG CRYAA CCR6
125 cytoplasmic body myopathy 10.8 UTRN DMD
126 intestinal schistosomiasis 10.8 MIR199A1 ICOSLG CCR6
127 prostate disease 10.8 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142 ICOSLG
128 autosomal dominant cerebellar ataxia 10.8 SERPINA3 MIR9-1 H2AC18 CRYAA
129 lymphatic system cancer 10.8 U2AF1 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142
130 disease of mental health 10.8 U2AF1 SERPINA3 RNU4ATAC MIR9-1 MIR199A1 MIR142
131 lymphatic system disease 10.8 U2AF1 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142
132 arteries, anomalies of 10.8 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1 MIR142
133 breast disease 10.8 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142 ICOSLG
134 spindle cell rhabdomyosarcoma 10.8 MYOG MYOD1 CRYAA
135 muscle cancer 10.8 SERPINA3 MYOG MYOD1 MIR9-1 MIR675 MIR199A1
136 male reproductive system disease 10.8 U2AF1 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142
137 intestinal disease 10.8 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1 MIR142
138 panuveitis 10.8 SERPINA3 ICOSLG CCR6
139 uterine anomalies 10.8 U2AF1 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1
140 lymphoma, non-hodgkin, familial 10.8 U2AF1 SERPINA3 MIR9-1 MIR199A1 MIR142 ICOSLG
141 respiratory system cancer 10.8 U2AF1 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142
142 female reproductive system disease 10.8 U2AF1 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142
143 mixed cell type cancer 10.8 SERPINA3 MYOG H2AC18
144 large intestine cancer 10.8 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1 MIR142
145 autosomal recessive disease 10.8 U2AF1 SERPINA3 RNU4ATAC MIR9-1 MIR221 ICOSLG
146 endocrine gland cancer 10.8 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1 MIR142
147 colonic disease 10.8 U2AF1 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1
148 bethlem myopathy 1 10.8 UTRN RYR1 DMD CRYAA
149 gastrointestinal system cancer 10.8 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1 MIR142
150 ullrich congenital muscular dystrophy 1 10.8 UTRN MYOD1 DMD CRYAA
151 gastrointestinal system disease 10.8 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1 MIR142
152 listeriosis 10.8 ICOSLG H2AC18 CCR6
153 skin disease 10.8 U2AF1 SERPINA3 MIR199A1 MIR142 ICOSLG H2AC18
154 herpangina 10.8 ICOSLG H2AC18 CCR6
155 myeloma, multiple 10.8 U2AF1 SERPINA3 MIR9-1 MIR675 MIR199A1 MIR142
156 rhabdoid cancer 10.8 MYOG MIR675 H2AC18
157 autoimmune disease of exocrine system 10.8 ICOSLG H2AC18 CCR6
158 urinary system disease 10.8 U2AF1 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1
159 respiratory failure 10.8 SERPINA3 RYR1 H2AC18 DMD CCR6
160 tonsil cancer 10.8 SERPINA3 MIR199A1 H2AC18
161 thoracic cancer 10.8 U2AF1 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1
162 immunodeficiency with hyper-igm, type 1 10.8 ICOSLG H2AC18 CCR6
163 bullous skin disease 10.8 SERPINA3 ICOSLG CCR6
164 reproductive system disease 10.8 U2AF1 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1
165 immune system disease 10.8 U2AF1 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142
166 peripheral nervous system disease 10.8 U2AF1 SERPINA3 RYR1 RNU4ATAC MIR142 ICOSLG
167 cardiovascular system disease 10.8 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142 ICOSLG
168 central nervous system disease 10.8 U2AF1 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142
169 respiratory system disease 10.8 U2AF1 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142
170 human immunodeficiency virus infectious disease 10.8 SERPINA3 ICOSLG H2AC18 CCR6
171 glucose metabolism disease 10.8 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1 MIR142
172 acquired metabolic disease 10.8 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1 MIR142
173 mesenchymal cell neoplasm 10.8 SERPINA3 MYOG MIR199A1
174 splenic disease 10.8 U2AF1 H2AC18 CCR6
175 coccidiosis 10.8 ICOSLG H2AC18 CCR6
176 autoimmune disease of skin and connective tissue 10.8 SERPINA3 ICOSLG CCR6
177 lung cancer susceptibility 3 10.8 U2AF1 SERPINA3 MIR9-1 MIR199A1 MIR142 ICOSLG
178 colonic benign neoplasm 10.8 SERPINA3 H2AC18 CCR6
179 ocular motility disease 10.8 SERPINA3 RYR1 CRYAA
180 hematologic cancer 10.8 U2AF1 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1
181 coronavirus infectious disease 10.8 SERPINA3 H2AC18 CCR6
182 leukemia, acute lymphoblastic 10.8 U2AF1 MIR9-1 MIR221 MIR199A1 MIR142 ICOSLG
183 pancreas disease 10.8 U2AF1 SERPINA3 MIR9-1 MIR675 MIR221 MIR199A1
184 leukemia, acute myeloid 10.8 U2AF1 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR142
185 squamous cell carcinoma, head and neck 10.8 U2AF1 MIR9-1 MIR221 MIR199A1 MIR142 ICOSLG
186 walker-warburg syndrome 10.8 UTRN POMGNT2 DMD B3GNT2
187 anus disease 10.8 ICOSLG H2AC18 CCR6
188 beckwith-wiedemann syndrome 10.8 RYR1 MYOD1 MIR675 H2AC18 DMD
189 hepatic vascular disease 10.8 U2AF1 MIR199A1 CCR6
190 nervous system disease 10.8 U2AF1 SERPINA3 RNU4ATAC MIR9-1 MIR221 MIR199A1
191 monoclonal gammopathy of uncertain significance 10.8 U2AF1 ICOSLG CCR6
192 thymus gland disease 10.8 ICOSLG H2AC18 CCR6
193 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.8 U2AF1 SERPINA3 RYR1 RNU4ATAC MIR9-1 MIR199A1
194 leukemia, chronic lymphocytic 10.8 U2AF1 MIR9-1 MIR221 MIR199A1 MIR142 ICOSLG
195 ureteral disease 10.8 MIR199A1 MIR142 CCR6
196 eye disease 10.8 U2AF1 SERPINA3 RNU4ATAC MIR9-1 MIR675 MIR199A1
197 rectal disease 10.8 ICOSLG H2AC18 CCR6
198 blood protein disease 10.8 ICOSLG H2AC18 CCR6
199 autosomal genetic disease 10.8 U2AF1 SERPINA3 RYR1 RNU4ATAC MIR9-1 MIR199A1
200 thymus cancer 10.8 ICOSLG H2AC18 CCR6
201 connective tissue disease 10.8 U2AF1 SERPINA3 RNU4ATAC MIR9-1 MIR675 MIR221
202 endocrine system disease 10.8 U2AF1 SERPINA3 RNU4ATAC MIR9-1 MIR675 MIR221
203 body mass index quantitative trait locus 11 10.8 SERPINA3 MIR675 MIR221 MIR199A1 MIR142 ICOSLG
204 diabetes mellitus, noninsulin-dependent 10.8 SERPINA3 MYOD1 MIR675 MIR199A1 MIR142 ICOSLG
205 suppression of tumorigenicity 12 10.8 U2AF1 SERPINA3 MIR199A1 H2AC18
206 lysosomal storage disease 10.8 SERPINA3 MIR199A1 H2AC18 CCR6
207 fungal infectious disease 10.8 ICOSLG H2AC18 CCR6
208 breast rhabdomyosarcoma 10.8 MYOG MYOD1
209 mycobacterium tuberculosis 1 10.8 SERPINA3 ICOSLG H2AC18 CCR6
210 lymph node disease 10.8 SERPINA3 ICOSLG CCR6
211 renal cell carcinoma, nonpapillary 10.8 MIR9-1 MIR221 MIR199A1 MIR142 ICOSLG H2AC18
212 exanthem 10.8 ICOSLG H2AC18 CCR6
213 nose disease 10.8 SERPINA3 ICOSLG CCR6
214 autoimmune disease of gastrointestinal tract 10.8 ICOSLG H2AC18 CCR6
215 marginal zone b-cell lymphoma 10.8 U2AF1 MIR142 CCR6
216 adrenal gland disease 10.8 SERPINA3 MIR675 CCR6
217 teeth hard tissue disease 10.8 SERPINA3 H2AC18 CCR6
218 x-linked recessive disease 10.8 UTRN U2AF1 SERPINA3 MYOG MYOD1 MIR675
219 b cell deficiency 10.8 RNU4ATAC ICOSLG CCR6
220 hypotrichosis 1 10.8 ICOSLG H2AC18 CCR6
221 x-linked monogenic disease 10.8 UTRN U2AF1 SERPINA3 MYOG MYOD1 MIR9-1
222 retinitis pigmentosa 10.8 U2AF1 SERPINA3 RNU4ATAC MYOD1 MIR142 H2AC18
223 degeneration of macula and posterior pole 10.8 SERPINA3 H2AC18 CRYAA
224 bone structure disease 10.8 RYR1 DMD CCR6
225 bladder sarcoma 10.8 SERPINA3 MYOG
226 cellulitis 10.8 SERPINA3 ICOSLG CCR6
227 cardiovascular organ benign neoplasm 10.8 SERPINA3 H2AC18 CCR6
228 germ cell and embryonal cancer 10.8 SERPINA3 MIR9-1 H2AC18
229 congenital muscular dystrophy-dystroglycanopathy type a5 10.8 POMGNT2 B3GNT2
230 pineal region teratoma 10.8 MYOG MYOD1
231 leukemia, chronic myeloid 10.8 U2AF1 MIR9-1 MIR199A1 MIR142 H2AC18
232 conventional leiomyosarcoma 10.8 MYOG MYOD1
233 hemophagocytic lymphohistiocytosis, familial, 1 10.8 MYOG MYOD1 DMD
234 prostate embryonal rhabdomyosarcoma 10.8 MYOG MYOD1
235 cerebellar disease 10.8 SERPINA3 RNU4ATAC H2AC18
236 lymphangioma 10.8 SERPINA3 H2AC18 CCR6
237 skeletal muscle neoplasm 10.8 MYOG MYOD1
238 urinary tract obstruction 10.7 MIR199A1 MIR142 CCR6
239 stomach disease 10.7 ICOSLG H2AC18 CCR6
240 lymphadenitis 10.7 SERPINA3 ICOSLG CCR6
241 pancreatic ductal adenocarcinoma 10.7 MIR221 MIR199A1 MIR142 CCR6
242 lens disease 10.7 SERPINA3 H2AC18 CRYAA
243 malignant fibrous histiocytoma 10.7 SERPINA3 MYOG MYOD1
244 in situ carcinoma 10.7 SERPINA3 MIR142 H2AC18
245 muscle tissue disease 10.7 UTRN U2AF1 SERPINA3 RYR1 RNU4ATAC MYOG
246 gastric squamous cell carcinoma 10.7 SERPINA3 CCR6
247 gallbladder sarcoma 10.7 MYOG MYOD1
248 prostate rhabdomyosarcoma 10.7 MYOG MYOD1
249 scrotum neoplasm 10.7 SERPINA3 MYOG
250 malignant fibrous histiocytoma of bone 10.7 SERPINA3 MYOD1
251 toxic encephalopathy 10.7 SERPINA3 MIR9-1 H2AC18
252 adult fibrosarcoma 10.7 MYOG MYOD1
253 retinal vascular disease 10.7 MIR199A1 H2AC18 CRYAA
254 nutritional deficiency disease 10.7 SERPINA3 H2AC18 CCR6
255 chromosomal deletion syndrome 10.7 MIR9-1 MIR142 H2AC18
256 central nervous system mesenchymal non-meningothelial tumor 10.7 MYOG MYOD1
257 hypomyelinating leukodystrophy 10.7 SERPINA3 H2AC18 EPRS1
258 prostate sarcoma 10.7 MYOG MYOD1
259 dystrophinopathies 10.6 UTRN DMD
260 malignant triton tumor 10.6 MYOG MYOD1
261 botryoid rhabdomyosarcoma 10.6 MYOG MYOD1
262 liver sarcoma 10.6 SERPINA3 MYOG
263 wilms tumor 1 10.6 U2AF1 SERPINA3 MYOG H2AC18
264 centronuclear myopathy 10.6 RYR1 MIR199A1 DMD
265 bone disease 10.5 SERPINA3 ICOSLG H2AC18 CCR6
266 pulmonary fibrosis, idiopathic 10.5 MIR199A1 MIR142 ICOSLG CCR6
267 cone-rod dystrophy, x-linked, 3 10.5 SERPINA3 CRYAA
268 myofibrillar myopathy 10.4 SERPINA3 DMD CRYAA
269 cholangitis, primary sclerosing 10.2 MIR199A1 ICOSLG CCR6
270 polymyositis 10.1
271 myotonia 10.0
272 myotonic dystrophy 9.9
273 muscular atrophy 9.9
274 malignant hyperthermia 9.9
275 periodic paralysis 9.9
276 dermatomyositis 9.8
277 myotonia congenita 9.8
278 glycogen storage disease 9.8
279 liver disease 9.8
280 fasciitis 9.8
281 macrophagic myofasciitis 9.8
282 hypotonia 9.8
283 oculopharyngeal muscular dystrophy 9.7
284 paramyotonia congenita of von eulenburg 9.7
285 temporal arteritis 9.7
286 spinal muscular atrophy 9.7
287 guillain-barre syndrome 9.7
288 panniculitis 9.7
289 lateral sclerosis 9.7
290 mitochondrial myopathy 9.7
291 malakoplakia 9.7
292 mycobacterium avium complex infections 9.7
293 dysphagia 9.7
294 clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly 9.6
295 hypertelorism 9.6
296 myotonia congenita, autosomal dominant 9.6
297 hypokalemic periodic paralysis, type 1 9.6
298 rheumatoid arthritis 9.6
299 stiff-person syndrome 9.6
300 strabismus 9.6
301 thrombocytopenic purpura, autoimmune 9.6
302 eosinophilic fasciitis 9.6
303 spinal muscular atrophy, type ii 9.6
304 miyoshi muscular dystrophy 1 9.6
305 myasthenia gravis 9.6
306 myotonia congenita, autosomal recessive 9.6
307 ataxia and polyneuropathy, adult-onset 9.6
308 rippling muscle disease 2 9.6
309 kawasaki disease 9.6
310 muscle hypertrophy 9.6
311 myopathy, distal, with rimmed vacuoles 9.6
312 alkuraya-kucinskas syndrome 9.6
313 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.6
314 peripheral vascular disease 9.6
315 angina pectoris 9.6
316 lambert-eaton myasthenic syndrome 9.6
317 scoliosis 9.6
318 miyoshi muscular dystrophy 9.6
319 myoglobinuria 9.6
320 tetanus 9.6
321 clubfoot 9.6
322 polyneuropathy 9.6
323 hypothyroidism 9.6
324 thymus lipoma 9.6
325 thoracic outlet syndrome 9.6
326 lipomatosis 9.6
327 purpura 9.6
328 lactic acidosis 9.6
329 intermittent claudication 9.6
330 postpoliomyelitis syndrome 9.6
331 chronic inflammatory demyelinating polyradiculoneuropathy 9.6
332 demyelinating polyneuropathy 9.6
333 subvalvular aortic stenosis 9.6
334 hyperthyroidism 9.6
335 myocarditis 9.6
336 pyomyositis 9.6
337 mitochondrial encephalomyopathy 9.6
338 mechanical strabismus 9.6
339 episodic ataxia 9.6
340 limb-girdle muscular dystrophy 9.6
341 mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes 9.6
342 multifocal motor neuropathy 9.6
343 thyrotoxic periodic paralysis 9.6
344 myopathy - thyrotoxic 9.6
345 swallowing disorders 9.6
346 thomsen's myotonia 9.6
347 progressive muscular dystrophy 9.6
348 qualitative or quantitative defects of sarcoglycan 9.6
349 congenital amyoplasia 9.6

Graphical network of the top 20 diseases related to Muscular Disease:



Diseases related to Muscular Disease

Symptoms & Phenotypes for Muscular Disease

Drugs & Therapeutics for Muscular Disease

Drugs for Muscular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 47, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 2, Phase 3 170277-31-3
2 Dermatologic Agents Phase 2, Phase 3
3 Gastrointestinal Agents Phase 2, Phase 3
4 Antirheumatic Agents Phase 2, Phase 3
5 Antimetabolites Phase 2
6 Hypolipidemic Agents Phase 2
7 Anticholesteremic Agents Phase 2
8 Lipid Regulating Agents Phase 2
9 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
10 Anti-Retroviral Agents Phase 2
11 Rosuvastatin Calcium Phase 2 147098-20-2
12 Calcium, Dietary Phase 2
13
Calcium Nutraceutical Phase 2 7440-70-2 271
14
Colchicine Approved Phase 1 64-86-8 2833 6167
15
Tacrolimus Approved, Investigational Phase 1 104987-11-3 445643 439492 6473866
16
Clotrimazole Approved, Vet_approved Phase 1 23593-75-1 2812
17
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
18 Anti-Infective Agents Phase 1
19 Immunosuppressive Agents Phase 1
20 Cyclosporins Phase 1
21 Antifungal Agents Phase 1
22 Immunologic Factors Phase 1
23 Calcineurin Inhibitors Phase 1
24 Tubulin Modulators Phase 1
25 Antimitotic Agents Phase 1
26
leucovorin Approved 58-05-9 6006 143
27
Methotrexate Approved 59-05-2, 1959-05-2 126941
28
Prednisone Approved, Vet_approved 53-03-2 5865
29
Azathioprine Approved 446-86-6 2265
30
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
31 Immunoglobulins
32 Antibodies
33 Rho(D) Immune Globulin
34 Immunoglobulins, Intravenous
35 gamma-Globulins
36 Hormones
37 Vitamin B Complex
38 Hormone Antagonists
39 glucocorticoids
40 Folic Acid Antagonists
41 Antineoplastic Agents, Hormonal
42 Folate
43 Vitamin B9
44 Anti-Inflammatory Agents
45 Tea
46 Pharmaceutical Solutions
47 Omega 3 Fatty Acid

Interventional clinical trials:

(showing 18, show less)
# Name Status NCT ID Phase Drugs
1 An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies Completed NCT00443222 Phase 2, Phase 3 Infliximab
2 Pilot Study of the Impact of Rosuvastatin Administration on Residual Chronic Immune Activation Under Antiretroviral Therapy: CESAR (Crestor En Sus Des AntiRétroviraux) Unknown status NCT01874743 Phase 2 Rosuvastatin 20 mg/day
3 Feasibility and Impact of Qigong as Compared to Aerobic Exercise in the Treatment of Childhood Chronic Musculoskeletal Pain: A Pilot Randomized Controlled Trial. Completed NCT00312234 Phase 2
4 An Open Non Randomized Comparative Study Exploring Drug Interaction Between Colchicine and Calcineurin Inhibitors in 2 Groups (Ciclosporin Group and Tacrolimus Group) of Renal Graft Recipients Completed NCT01160276 Phase 1 cyclosporine+colchicine;tacrolimus
5 The Evaluation of Therapeutic Riding in Children and Adolescent With Kinetic Deficits Because of Neuromuscular Disease. Completed NCT01621984 Phase 1
6 Prognstic Factors Affecting Duchenne Muscular Dystrophy Unknown status NCT03372655
7 Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells Unknown status NCT02404298 IVIg
8 Characterization of Skeletal Muscle Using Magnetic Resonance Elastography (MRE) Completed NCT00588432
9 Pre-frailty Status Increases the Risk of Rehospitalization and Mortality in Patients After Cardiac Surgery Without Complications Completed NCT03949439
10 High Intensity Interval Training in Patients With Facioscapulohumeral Muscular Dystrophy Completed NCT02159963
11 Outcome of Muscle Function and Disease Activity in Patients With Recent Onset Polymyositis and Dermatomyositis - a 1-year Follow-up Register Study Completed NCT01813617 Immunosuppressive Agents
12 Can Secondary Total Elbow Arthroplasty After Failed Internal Fixation or Non-operative Treatment of Distal Humeral Fractures Achieve Equal Results as Primary Arthroplasty? Completed NCT03302533
13 Effect of EPA and HMB on Diaphragm and Limb Muscle Strength in Mechanically Ventilated Patients Completed NCT01270516 HMB, hydroxymethylbutyrate;EPA, eicosapentaenoic acid;Saline
14 Tactile Sensitivity of the Oral Tissues and Chewing Efficiency Are Impaired in Stroke Patients Completed NCT02822391
15 Non-invasive Molecular Imaging to Determine Hemoglobin and Collagen Levels in Muscles Before and After Exercise, and Over Time Active, not recruiting NCT03979157
16 PReventing EXtubation FAILure by Cough Assistance and NIV in a Population Selected on Cough Peak Flow Not yet recruiting NCT03562000
17 Post Market Study of the Electrophysiological Course of Low Back Pain Using CERSR Technology Terminated NCT01403870
18 Quantitative Assessment of Train of Four Device for Patients Receiving Neuromuscular Blockade Withdrawn NCT02591108

Search NIH Clinical Center for Muscular Disease

Genetic Tests for Muscular Disease

Anatomical Context for Muscular Disease

MalaCards organs/tissues related to Muscular Disease:

40
Brain, Skeletal Muscle, Bone, Heart, Testes, Bone Marrow, Liver

Publications for Muscular Disease

Articles related to Muscular Disease:

(showing 296, show less)
# Title Authors PMID Year
1
Urinary Dimethylamine (DMA) and Its Precursor Asymmetric Dimethylarginine (ADMA) in Clinical Medicine, in the Context of Nitric Oxide (NO) and Beyond. 61
32545708 2020
2
Quantitative Estimation of Passive Elastic Properties of Individual Skeletal Muscle in Vivo Using Normalized Elastic Modulus-Length Curve. 61
32286954 2020
3
Mortality and Cause of Death in Patients With Vertebral Fractures: A Longitudinal Follow-Up Study Using a National Sample Cohort. 61
31568093 2020
4
Quantitation of cytidine-5'-monophospho-N-acetylneuraminic acid in human leukocytes using LC-MS/MS: method development and validation. 61
31691999 2020
5
Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy. 61
31957953 2020
6
Viral vectors for gene delivery to the inner ear. 61
32199720 2020
7
Myositis Induced by Isotretinoin: A Case Report and Literature Review. 61
31958335 2020
8
Deep Learning Technique for Musculoskeletal Analysis. 61
32030670 2020
9
Lameness, generalised myopathy and myalgia in an adult cat with toxoplasmosis. 61
32206329 2020
10
Obstetric management of a woman with limb-girdle muscular dystrophy type 2i and dilated cardiomyopathy. 61
31853262 2019
11
Transcriptomic Analysis Reveals Involvement of the Macrophage Migration Inhibitory Factor Gene Network in Duchenne Muscular Dystrophy. 61
31752120 2019
12
Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice. 61
31479430 2019
13
[Elevated liver enzyme levels; not exclusive to liver disease]. 61
32073783 2019
14
Genetic regulatory variation in populations informs transcriptome analysis in rare disease. 61
31601707 2019
15
Serum lactate dehydrogenase activity and its isoenzyme patterns in patients with pectus excavatum. 61
31737320 2019
16
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy. 61
31394715 2019
17
Growth Hormone Increases Bone Toughness and Decreases Muscle Inflammation in Glucocorticoid-Treated Mdx Mice, Model of Duchenne Muscular Dystrophy. 61
31188496 2019
18
[Nutritional problematic related to frailty and sarcopenia in older]. 61
31368339 2019
19
Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. 61
29770465 2019
20
Microfluidic devices for disease modeling in muscle tissue. 61
30193908 2019
21
Interferon Chemokine Score and Other Cytokine Measures Track With Changes in Disease Activity in Patients With Juvenile and Adult Dermatomyositis. 61
31777784 2019
22
Heart Transplantation Ameliorates Ambulation Capacity in Patients With Muscular Dystrophy - An Analysis of 9 Cases. 61
30686808 2019
23
A nationwide survey on tracheostomy for very-low-birth-weight infants in Japan. 61
30525314 2019
24
Musculoskeletal Manifestations of Sarcoidosis: A Review Article. 61
29692254 2019
25
Muscle endurance deficits in myositis patients despite normal manual muscle testing scores. 61
30028529 2019
26
Experiences with bariatric surgery in patients with facioscapulohumeral dystrophy and myotonic dystrophy type 1: A qualitative study. 61
30342904 2018
27
Cross-section and feasibility study on the non-invasive evaluation of muscle hemodynamic responses in Duchenne muscular dystrophy by using a near-infrared diffuse optical technique. 61
30319901 2018
28
Immunophenotyping lymphocyte and acute phase proteins in canine X-linked muscular dystrophy. 61
30304229 2018
29
Prevalence and Risk Factors for Musculoskeletal Pain in Keyboard Musicians: A Systematic Review. 61
29705171 2018
30
A Young Patient with Emery-Dreifuss Muscular Dystrophy Treated with Endovascular Therapy for Cardioembolic Stroke: A Case Report. 61
30191544 2018
31
Pathological manifestations of Farber disease in a new mouse model. 61
29908121 2018
32
Characterization of miRNA transcriptome profiles related to breast muscle development and intramuscular fat deposition in chickens. 61
29737555 2018
33
Isometric Finger Pose Recognition with Sparse Channel SpatioTemporal EMG Imaging. 61
30441518 2018
34
Does muscle biopsy change the treatment of pediatric muscular disease? 61
29845315 2018
35
Feasibility of peripheral nerve MR neurography using diffusion tensor imaging adapted to skeletal muscle disease. 61
28795588 2018
36
Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. 61
29474663 2018
37
Energy expenditure, body composition, and prevalence of metabolic disorders in patients with Duchenne muscular dystrophy. 61
28869151 2018
38
Application of Quantitative Pharmacology Approaches in Bridging Pharmacokinetics and Pharmacodynamics of Domagrozumab From Adult Healthy Subjects to Pediatric Patients With Duchenne Muscular Disease. 61
29023829 2018
39
Tolerance of chronic HDACi treatment for neurological, visceral and lung Niemann-Pick Type C disease in mice. 61
29497113 2018
40
Electrophysiological and histopathological findings of muscular disease suspected as myotonic dystrophy in a Shiba dog. 61
29311426 2018
41
In Vitro Evaluation of Exon Skipping in Disease-Specific iPSC-Derived Myocytes. 61
30171542 2018
42
Cardiac Dysfunction in Duchenne Muscular Dystrophy Is Less Frequent in Patients With Mutations in the Dystrophin Dp116 Coding Region Than in Other Regions. 61
29874176 2018
43
Brain and heart magnetic resonance imaging/spectroscopy in duchenne muscular dystrophy. 61
28981141 2017
44
Anaesthetic management of patients with myopathies. 61
28719515 2017
45
Imaging of Myopathies. 61
28774448 2017
46
Polyurethane acrylates as effective substrates for sustained in vitro culture of human myotubes. 61
28435079 2017
47
Craniofacial Manifestations in Severe Nemaline Myopathy. 61
28468212 2017
48
Cutaneous manifestations in Steinert’s disease. Apropos of four clinical cases. 61
28702961 2017
49
The Use of Korean Medicine to Treat Patients with Spinobulbar Muscular Atrophy, Kennedy's Disease - A Case Study. 61
28392964 2017
50
Occurrence of Emery-Dreifuss muscular dystrophy in a rural setting of Cameroon: a case report and review of the literature. 61
28069046 2017
51
Correspondence and challenges as neurologists to Kumamoto Earthquakes in 2016. 61
27890884 2016
52
Congenital muscular dystrophy and epilepsy: a prospective case series of pediatric patients. 61
28078877 2016
53
Primary thoracic muscle tuberculosis: two case reports. 61
27531321 2016
54
MEF2D and MEF2C pathways disruption in sporadic and familial ALS patients. 61
26921792 2016
55
Regulation of Skeletal Muscle by microRNAs. 61
27347893 2016
56
Differential Expression of Cardiac Troponin T and I in a Patient with Isolated Skeletal Muscular Sarcoidosis. 61
27803423 2016
57
Ageing with Muscular Disease. 61
28144383 2016
58
[Juvenile dermatomyositis and new autoantibodies: Cases and review]. 61
26598044 2015
59
X-ray phase-contrast tomography for high-spatial-resolution zebrafish muscle imaging. 61
26564785 2015
60
CUG-BP1 regulates RyR1 ASI alternative splicing in skeletal muscle atrophy. 61
26531141 2015
61
Nutrition Considerations in Duchenne Muscular Dystrophy. 61
25977513 2015
62
Cardiac involvement in Duchenne and Becker muscular dystrophy. 61
26225202 2015
63
Recessive mutations in the α3 (VI) collagen gene COL6A3 cause early-onset isolated dystonia. 61
26004199 2015
64
[Analysis of clinical features of 6 patients with infantile type glycogen storage disease type II]. 61
26310554 2015
65
Quickly progressive amyotrophy of the thigh: An unusual cause of rapid chondrolysis of the knee. 61
25680228 2015
66
Hyponatremia and hypokalemia as risk factors for falls. 61
25226820 2015
67
Reduced inotropic reserve is predictive of further degradation in left ventricular ejection fraction in patients with Duchenne muscular dystrophy. 61
25823361 2015
68
Clinical and muscle imaging findings in 14 mainland chinese patients with oculopharyngodistal myopathy. 61
26039504 2015
69
[Hereditary hypokaliaemic periodic paralysis in a 13-year-old boy]. 61
25497649 2014
70
Quantitative proteomic analysis reveals metabolic alterations, calcium dysregulation, and increased expression of extracellular matrix proteins in laminin α2 chain-deficient muscle. 61
24994560 2014
71
Skeletal muscle tissue engineering: methods to form skeletal myotubes and their applications. 61
24320971 2014
72
Validation of ambiguous MLPA results by targeted next-generation sequencing discloses a nonsense mutation in the DMD gene. 61
24892813 2014
73
Be careful about abdominal discomfort in adult patients with muscular dystrophy. 61
25189677 2014
74
[Autoantibody profile in myositis]. 61
24387952 2014
75
Statistical insights into major human muscular diseases. 61
24569163 2014
76
Elevations in serum muscle enzyme activities in racehorses due to unaccustomed exercise and training. 61
24415762 2014
77
Systematic Analysis of the Multiple Bioactivities of Green Tea through a Network Pharmacology Approach. 61
25525446 2014
78
The Tudor protein survival motor neuron (SMN) is a chromatin-binding protein that interacts with methylated lysine 79 of histone H3. 61
23750013 2013
79
Muscle diseases with prominent joint contractures: Main entities and diagnostic strategy. 61
24021317 2013
80
[Unexplained, subclinical chronically elevated transaminases]. 61
23623710 2013
81
Restless legs syndrome associated with exercise intolerance: Data from a retrospective observational clinical neuromuscular center study. 61
24011981 2013
82
Cross-cultural adaptation and validation of the Brazilian version of the Wisconsin Brief Pain Questionnaire. 61
23219149 2013
83
Disuse osteoporosis of the upper limb: assessment of thirty patients. 61
24133531 2013
84
Vitamin D assays: past and present debates, difficulties, and developments. 61
23314742 2013
85
Circuit modeling of the electrical impedance: II. Normal subjects and system reproducibility. 61
23354000 2013
86
Isometric and eccentric force generation assessment of skeletal muscles isolated from murine models of muscular dystrophies. 61
23407283 2013
87
Molecular characterization of an X(p21.2;q28) chromosomal inversion in a Duchenne muscular dystrophy patient with mental retardation reveals a novel long non-coding gene on Xq28. 61
23223008 2013
88
Lipomatous muscular 'dystrophy' of Piedmontese cattle. 61
22717052 2012
89
Thin, a Trim32 ortholog, is essential for myofibril stability and is required for the integrity of the costamere in Drosophila. 61
23071324 2012
90
The first Italian patient with oculopharyngodistal myopathy: case report and considerations on differential diagnosis. 61
22652077 2012
91
Use of mid-humeral block of the radial, ulnar, musculocutaneous and median (RUMM block) nerves for extensor carpi radialis muscle biopsy in a conscious dog with generalized neuro-muscular disease. 61
22574755 2012
92
Ginevra de Benci's portrait: had the lady a myopathic face? 61
22005947 2012
93
In Silico Models to Discriminate Compounds Inducing and Noninducing Toxic Myopathy. 61
27478175 2012
94
[Development of an ultrasound-mediated nucleic acid delivery system for treating muscular dystrophies]. 61
23208045 2012
95
[The limitation of MB isoenzyme of creatine kinase mass in assess myocardial injury with muscular disease]. 61
22153008 2011
96
Responsiveness of four participation measures to changes during and after outpatient rehabilitation. 61
22031346 2011
97
Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. 61
21505953 2011
98
Wilmington robotic exoskeleton: a novel device to maintain arm improvement in muscular disease. 61
21654447 2011
99
TMEM43 mutations in Emery-Dreifuss muscular dystrophy-related myopathy. 61
21391237 2011
100
The costamere bridges sarcomeres to the sarcolemma in striated muscle. 61
24039381 2011
101
Early and long-term outcome after tracheostomy in children. 61
20667029 2011
102
Statistical Test of Expression Pattern (STEPath): a new strategy to integrate gene expression data with genomic information in individual and meta-analysis studies. 61
21481242 2011
103
Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. 61
21479190 2011
104
Therapeutic effects of anabolic androgenic steroids on chronic diseases associated with muscle wasting. 61
21158691 2011
105
Morphologic imaging in muscular dystrophies and inflammatory myopathies. 61
20449587 2010
106
[How can we diagnose and better understand inflammatory myopathies? The usefulness of auto-antibodies]. 61
20655695 2010
107
[Surgical approach to sialorrhea: a casuistic review and evaluation of grade of satisfaction]. 61
21520552 2010
108
Myotonic dystrophy initially presenting as tachycardiomyopathy successful catheter ablation of atrial flutter. 61
20871860 2010
109
[Amyotrophic lateral sclerosis]. 61
20726497 2010
110
An adult myometrial pluripotential precursor that promotes healing of damaged muscular tissues. 61
20668309 2010
111
Embryonic-like stem cell derived from adult bone marrow: immature morphology, cell surface markers, ultramicrostructure and differentiation into multinucleated fibers in vitro. 61
20385079 2010
112
Leishsmania (Leishmania) amazonensis infection: Muscular involvement in BALB/c and C3H.HeN mice. 61
19944691 2010
113
A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancer. 61
21358881 2010
114
HyperCKemia as a biomarker for muscular diseases. 61
20499036 2010
115
Control of the upper body movements during level walking in patients with facioscapulohumeral dystrophy. 61
19782569 2010
116
[Domiciliary non-invasive positive pressure ventilation (NPPV) care]. 61
20443419 2009
117
Zebrafish muscular disease models towards drug discovery. 61
23485083 2009
118
Unusual presentations of eosinophilic gastroenteritis: case series and review of literature. 61
19418590 2009
119
Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2. 61
19838336 2009
120
Muscular dystrophy with reduced beta-sarcoglycan in a cat. 61
19203767 2009
121
[Frontline studies on Duchenne muscular dystrophy treatment]. 61
19517771 2009
122
A new phenotype of dysferlinopathy with congenital onset. 61
19084402 2009
123
[From muscular disease to myology]. 61
19209653 2008
124
[Anesthetic management of patients with muscular disease?]. 61
19209658 2008
125
[Ocular disturbances in neuromuscular disorders]. 61
18808764 2008
126
Disorders of paravertebral lumbar muscles: from pathology to cross-sectional imaging. 61
18463867 2008
127
Using immunoglobulins in muscular disease treatment. 61
18613765 2008
128
AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis. 61
18434328 2008
129
[Biochemical cause of muscular disease discovered]. 61
18390279 2008
130
Clinical presentation and pathology of sarcocystosis in psittaciform birds: 11 cases. 61
18459322 2008
131
Clinical and molecular diagnosis of a Costa Rican family with autosomal recessive myotonia congenita (Becker disease) carrying a new mutation in the CLCN1 gene. 61
18624224 2008
132
[Physical therapy]. 61
18186276 2008
133
Rapid prenatal diagnosis of spinal muscular atrophy by denaturing high-performance liquid chromatography system. 61
18720039 2008
134
Developmental regulation of muscleblind-like (MBNL) gene expression in the chicken embryo retina. 61
18095352 2008
135
Continuous negative extrathoracic pressure combined with high-frequency oscillation improves oxygenation with less impact on blood pressure than high-frequency oscillation alone in a rabbit model of surfactant depletion. 61
17971241 2007
136
Psychogenic camptocormia. 61
17712851 2007
137
Estimated prevalence of polysaccharide storage myopathy among overtly healthy Quarter Horses in the United States. 61
17764437 2007
138
Anaesthetic considerations for patients with a pre-existing neurological deficit: are neuraxial techniques safe? 61
17488315 2007
139
[Clinical development of acid alpha-glucosidase for the treatment of Pompe disease]. 61
17546777 2007
140
[Pulmonary atelectasis in patients with neurological or muscular disease; gravity-related lung compression by the heart and intra-abdominal organs on persistent supine position]. 61
17094560 2006
141
Service provision for adults with long-term disability: a review of services for adults with chronic neuromuscular conditions in the United Kingdom. 61
16427286 2006
142
Sonographically guided percutaneous muscle biopsy in diagnosis of neuromuscular disease: a useful alternative to open surgical biopsy. 61
16371549 2006
143
[Carrier detection in Duchenne/Becker muscular dystrophy in the families in which the DNA of the affected person is not available]. 61
17028400 2006
144
Targeting the respiratory muscles of fetal sheep for prenatal gene therapy for Duchenne muscular dystrophy. 61
16157120 2005
145
Effects of non-contractile inclusions on mechanical performance of skeletal muscle. 61
15797585 2005
146
Creatine kinase MB (CK-MB) in benign paroxysmal vertigo of childhood: a new diagnostic marker. 61
15812463 2005
147
Plectin deficient epidermolysis bullosa simplex with 27-year-history of muscular dystrophy. 61
15659326 2005
148
[Anesthesia in hereditary peripheral muscular disease]. 61
15786909 2005
149
[Vaccine adjuvants and macrophagic myofasciitis]. 61
15653065 2005
150
The value of basic science in clinical diagnosis: creating coherence among signs and symptoms. 61
15612907 2005
151
[Successful treatment with infliximab of a patient with refractory sarcoidosis]. 61
15626311 2004
152
[Cardiac manifestations of laminopathies]. 61
16008174 2004
153
Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy. 61
15718211 2004
154
Gene therapy for muscular disease. 61
15364061 2004
155
Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. 61
15145337 2004
156
Targeting the immune system to improve ventilatory function in muscular dystrophy. 61
14707767 2004
157
[Macrophagic myofasciitis: inflammatory, vaccination-associated muscular disease]. 61
14593574 2003
158
Bone mineral density and bone metabolism in Duchenne muscular dystrophy. 61
12897980 2003
159
[Suspected muscular disease: what to do?]. 61
12956033 2003
160
Neuropathology considerations: clinical and SEMG/biofeedback applications. 61
12827988 2003
161
[Vaccine adjuvants and macrophagic myofasciitis]. 61
15146582 2003
162
[How should a muscular disease be studied?]. 61
15095727 2003
163
Genetic aspects of Labrador Retriever myopathy. 61
12443679 2002
164
[Biceps crural myositis after an insect bite]. 61
12481394 2002
165
Inhibition of muscle differentiation by the novel muscleblind-related protein CHCR. 61
12297108 2002
166
[Camptocormia: an infrequent muscular disease]. 61
12420634 2002
167
[Anesthesia for cesarean section in a patient with McArdle disease and hereditary dilated cardiomyopathy]. 61
12134596 2002
168
Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. 61
11840450 2002
169
[Aldolase]. 61
11797371 2001
170
Muscular degeneration in the absence of dystrophin is a calcium-dependent process. 61
11696327 2001
171
[When should you consider a muscular disease?]. 61
11265420 2001
172
Delineation of CTG repeats and clinical features in a Taiwanese myotonic dystrophy family. 61
11254171 2001
173
Cysticercosis of the triceps--an unusual pseudotumor: case report and review. 61
11153991 2001
174
Natural history of cardiac involvement in myotonic dystrophy (Steinert's disease): a 13-year follow-up study. 61
11186144 2000
175
Apoptotic features accompany acute quadriplegic myopathy. 61
10994008 2000
176
[Fukuyama type congenital muscular dystrophy (cerebro-muscular disease). A case report]. 61
11008300 2000
177
Vaginal delivery in a woman with limb-girdle muscular dystrophy. A case report. 61
10900585 2000
178
[Diagnosis of muscular disease]. 61
10776061 2000
179
[Subcutaneous tenotomy of Achille's tendon in adults for ankle stiffness. A review of 80 cases]. 61
10669823 2000
180
Treatment of cricopharyngeal dysfunction by endoscopic laser myotomy. 61
10909025 2000
181
Neurotrophic factors and neuro-muscular disease: II. GDNF, other neurotrophic factors, and future directions. 61
10417781 1999
182
Identification of survival motor neuron as a transcriptional activator-binding protein. 61
10369867 1999
183
A novel mutation in the gene for the adult skeletal muscle sodium channel alpha-subunit (SCN4A) that causes paramyotonia congenita of von Eulenburg. 61
10369308 1999
184
Stabilization of eyelid height after aponeurotic ptosis repair. 61
10080208 1999
185
Identification of novel mutations in the MTM1 gene causing severe and mild forms of X-linked myotubular myopathy. 61
10502779 1999
186
Genomic organization of the MTM1 gene implicated in X-linked myotubular myopathy. 61
9781038 1998
187
[Genetic diagnosis of Duchenne/Becker muscular dystrophy; clinical application and problems]. 61
9545779 1998
188
Severe congenital nemaline myopathy: a personal perspective. 61
9526359 1998
189
Effect of recent cocaine use on the specificity of cardiac markers for diagnosis of acute myocardial infarction. 61
9489972 1998
190
[Genetic aspects (analysis and diagnosis) of muscular diseases--recent advances and future prospects]. 61
9436417 1997
191
Macroaspartasemia as a cause of isolated elevation of aspartate aminotransferase--its biochemical and physiological characteristics. 61
9439157 1997
192
[Progressive external ophthalmoplegia of mitochondrial origin: contribution of morphological and molecular studies]. 61
9296156 1997
193
Craniofacial abnormalities associated with congenital fiber type disproportion myopathy. 61
9484111 1997
194
[The structure of the diagnosis of neuromuscular diseases (the examination chart of outpatients for computer analysis)]. 61
9139509 1997
195
Cardiac involvement in facio-scapulo-humeral muscular dystrophy: a family study using Thallium-201 single-photon-emission-computed tomography. 61
8994104 1996
196
Elevated aminotransferase activity as an indication of muscular dystrophy: case reports and review of the literature. 61
9193775 1996
197
X-linked myotubular myopathy: refinement of the critical gene region. 61
8887957 1996
198
Analysis of dystrophin in muscular diseases by two-dimensional gel electrophoresis using agarose gels in the first dimension. 61
8711982 1996
199
[Granulomatous idiopathic myositis at pediatric onset. Description of a case and a review of literature]. 61
8926967 1996
200
Linkage analyses in tibial muscular dystrophy. 61
8666419 1996
201
[Nemalinic myopathy with intracytoplasmic spheroid bodies: report of a case]. 61
8736155 1996
202
[Myasthenia and pregnancy. Two case reports]. 61
8690867 1996
203
The toxic and abortifacient effects of ponderosa pine. 61
8826003 1996
204
Is camptocormia a primary muscular disease? 61
7631230 1995
205
Inspiratory muscle training during treatment with corticosteroids in humans. 61
7705113 1995
206
A decision support system for diagnostic consultation in laboratory tests. 61
8591361 1995
207
Identification of new mutations in two phosphoglycerate kinase (PGK) variants expressing different clinical syndromes: PGK Créteil and PGK Amiens. 61
8043870 1994
208
Chronic eosinophilic pneumonia as a presenting feature of Churg-Strauss syndrome. 61
8050532 1994
209
Dual-energy X-ray absorptiometry in neuromuscular diseases. 61
8170490 1994
210
Swallowing disorders in muscular diseases: functional assessment and indications of cricopharyngeal myotomy. 61
8162870 1994
211
[Anesthetic problems and postoperative care in the surgery for scoliosis]. 61
7818011 1994
212
Peripheral neuromuscular manifestations in systemic sclerosis (scleroderma). 61
8413372 1993
213
Actin-dystrophin interface. 61
8399191 1993
214
The effect of ventilatory muscle training on respiratory function and capacity in ambulatory and bed-ridden patients with neuromuscular disease. 61
8257974 1993
215
Myasthenia gravis with polyhydramnios in the fetus of an asymptomatic mother. 61
8372081 1993
216
Operation of controls on consumer products by physically impaired users. 61
8349290 1993
217
Arterial delivery of myoblasts to skeletal muscle. 61
1461375 1992
218
[A case of congenital muscular dystrophy with changes in the white matter of the brain]. 61
1454126 1992
219
[Quantification of the diameter of muscular fibres in the course of the development of the quadriceps]. 61
1790348 1991
220
The effect of neuromuscular diseases on the development of dental and occlusal characteristics. 61
1891607 1991
221
[Myocardial involvement in 2 women, carriers of Duchenne de Boulogne muscular dystrophy]. 61
2048927 1991
222
[Ceruloplasmin in patients with Duchenne muscular dystrophy]. 61
1842117 1991
223
[Limb-girdle dystrophy and pregnancy: a case report]. 61
1791291 1991
224
Cytochrome c oxidase deficient fibres in the limb muscle and diaphragm of man without muscular disease: an age-related alteration. 61
1965203 1990
225
Magnetic resonance imaging of primary skeletal muscle diseases: patterns of distribution and severity of involvement. 61
2268764 1990
226
Noninvasive estimation of the location of the end plate in the human masseter muscle using surface electromyograms with an electrode array. 61
2130160 1990
227
[Neuromuscular diseases and respiratory insufficiency in newborn infants]. 61
2234980 1990
228
[Hyposelenoses]. 61
2128681 1990
229
Ehlers-Danlos syndrome, clotting disorders and muscular dystrophy. 61
2512864 1989
230
Myopathy associated with AIDS. 61
2793415 1989
231
[Auricular flutter preceding by several years the discovery of Steinert's disease. 3 cases]. 61
2660734 1989
232
[Specific cardiomyopathy caused by high dose cyclophosphamide immediately after bone marrow transplantation]. 61
2671436 1989
233
Hyperestrogenemia in neuromuscular diseases. 61
2926448 1989
234
Condylar cartilage in the muscular dystrophic mouse. 61
2916467 1989
235
Congenital muscular dystrophy and cerebellar vermis agenesis in two brothers. 61
3215750 1988
236
Effects of thyroid hormones on skeletal muscle bioenergetics. In vivo phosphorus-31 magnetic resonance spectroscopy study of humans and rats. 61
3384946 1988
237
[A new inflammatory muscular disease: inclusion-body myositis]. 61
2835126 1987
238
Becker and limb-girdle muscular dystrophy associated with pituitary dwarfism. 61
3655848 1987
239
[Long-term hypertransaminasemia disclosing a muscular disease]. 61
3619584 1987
240
[Oral occlusion pressure in scoliosis and neuromuscular syndromes]. 61
3619564 1987
241
[Histogenesis, degeneration, regeneration and adaptation, aging and compensation in the skeletal muscles]. 61
3324552 1987
242
[AMP deaminase deficiency (myoadenylate deaminase). Disease or syndrome?]. 61
3823775 1986
243
Congenital muscular dystrophy and cerebral CT scan anomalies. Results of a collaborative study of the Société de Neurologie Infantile. 61
3091775 1986
244
[Development and effectiveness of a slit type--fenestrated tracheostomy tube in patients with respiratory muscular disease]. 61
3784170 1986
245
Magnetic resonance spectroscopy of the musculoskeletal system. 61
3459210 1986
246
Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. 61
3859873 1985
247
Myotonic dystrophy-like disease in a dog. 61
3972711 1985
248
[Unusual muscular involvement in ankylosing spondylitis]. 61
4001805 1985
249
Respiratory failure as initial symptom of acid maltase deficiency. 61
6429285 1984
250
[Electrodiagnosis of caudal cranial nerve disorders in infants and small children]. 61
6727496 1984
251
Episodic astigmatism heralding generalized myopathy: report of a case managed with a new type of soft contact lens. 61
6709330 1984
252
Tubular aggregates in a case of osteomalacic myopathy due to anticonvulsant drugs. 61
6705322 1984
253
[Malignant hyperthermia]. 61
6349413 1983
254
[Centronuclear myopathy. Apropos of a new case]. 61
6302904 1983
255
[A forgotten muscular dystrophy: Ullrich's disease]. 61
6648205 1983
256
A morphological study of non-Japanese congenital muscular dystrophy associated with cerebral lesions. 61
6412578 1983
257
[Echocardiographic studies in primary muscular disease]. 61
7109956 1982
258
Anaesthetic considerations in patients with muscular dystrophy undergoing spinal fusion and Harrington rod insertion. 61
7074403 1982
259
[Myoglobinuria following anesthesia (author's transl)]. 61
7103673 1982
260
[Muscular disease of X-linked autosomal recessive transmission with early muscular retractions and cardiac conduction disorders]. 61
6891495 1982
261
[A patient with a muscular disease! What can we still do?]. 61
6913277 1981
262
Clinical importance of clofibrate induced increase of creatine kinase catalytic activity concentration in serum. 61
7276838 1981
263
Chronic primary intestinal pseudo-obstruction. 61
6893876 1981
264
[Reducing body myopathy--ultrastructure and classification (author's transl)]. 61
6269277 1981
265
Pathomechanics and management of scoliosis in Friedreich ataxia patients: preliminary report. 61
7214253 1980
266
Simple electrophoretic technique for creatine kinase MM isozyme in neonatal Duchenne muscular disease screening using dried blood samples. 61
7398089 1980
267
No sex difference in mutations rates of Duchenne muscular dystrophy. 61
7381863 1980
268
[Neurological and muscular manifestations of thalassemia major (author's transl)]. 61
7469696 1980
269
[Change in heart function in Duchênne de Boulogne myopathies at the severe progressive stage]. 61
106797 1978
270
[Significance of speckled staining of epidermal nuclei in direct immunofluorescence. 10 cases (author's transl)]. 61
353722 1978
271
[Landouzy-Dejerine syndrome. Evolution of the concept of facio-scapulo-humeral amyotrophia]. 61
929032 1977
272
[Subvalvular aortic stenosis, dysmorphic familial syndrome and peripheral muscular disease]. 61
141245 1977
273
Neurological aspects of sinoatrial heart block. 61
950569 1976
274
Quantitation of a urinary tetrasaccharide by gas chromatography and mass spectrometry. 61
817751 1976
275
[Etiopathogenic considerations on a case of talipes equinovarus due to parasitic muscular disease]. 61
1024848 1976
276
[A curable muscular disease]. 61
1250450 1976
277
[Course of a model cutaneous inflammation on the cellular level in neuro-muscular disease]. 61
1104204 1975
278
Alveolar hypoventilation and hyperosmnia in myotonic dystrophy. 61
172608 1975
279
Correction of severe open-bite associated with muscular disease. Report of a case. 61
1054459 1975
280
[Gamma-glutamyl-transpeptidase in muscular disease]. 61
237311 1975
281
Myoglobin in primary muscular disease. I. Duchenne muscular dystrophy. II. Muscular dystrophy of distal type. 61
4590363 1973
282
[Stomach rupture in a case of a child affected by congenital muscular disease following the ingestion of gaseous drink]. 61
5147710 1971
283
[Muscular disease in scapuloperoneal distribution]. 61
5547227 1971
284
Genetic approaches to the nosology of muscular disease: myotonias and similar diseases. 61
5293617 1971
285
Strabismus as a possible sign of latent muscular disease predisposing to suxamethonium-induced muscular injury. 61
5450203 1970
286
[Importance of enzyme histochemistry in the diagnosis of neurogenic muscular disease. Discussion of some special aspects]. 61
4255923 1969
287
Laboratory diagnostic measures in generalized muscular disease. 61
5337117 1967
288
Chemical laboratory studies in muscular disease. 61
6037161 1967
289
[Electromyographic contribution to the study of muscular disease in thyreopathy]. 61
5995939 1966
290
THE DIAGNOSTIC VALUE OF SERUM CREATINE KINASE IN NEUROMUSCULAR AND MUSCULAR DISEASE. 61
14261970 1965
291
[DIFFERENTIAL DIAGNOSTIC CONSIDERATIONS IN A CASE OF MUSCULAR DISEASE]. 61
14177184 1964
292
A TEST OF NERVE CONDUCTION TO MUSCLES OF THE SHOULDER GIRDLE AS AN AID IN THE DIAGNOSIS OF PROXIMAL NEUROGENIC AND MUSCULAR DISEASE. 61
14175285 1964
293
Muscular disease. 61
13902052 1961
294
Abnormal hepatic tests in muscular disease. 61
13660530 1959
295
[Circulatory disorders during muscular disease; arteriographic research]. 61
13454097 1957
296
Hyperinsulinism and neuromuscular disorders; a consideration of the association of pancreatic adenoma with wasting states. 61
13032800 1953

Variations for Muscular Disease

Expression for Muscular Disease

Search GEO for disease gene expression data for Muscular Disease.

Pathways for Muscular Disease

Pathways related to Muscular Disease according to GeneCards Suite gene sharing:

(showing 1, show less)
# Super pathways Score Top Affiliating Genes
1 10.5 MYOD1 MIR9-1 MIR221 MIR199A1

GO Terms for Muscular Disease

Biological processes related to Muscular Disease according to GeneCards Suite gene sharing:

(showing 10, show less)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.88 MIR9-1 MIR675 MIR221 MIR199A1 MIR142
2 skeletal muscle tissue development GO:0007519 9.54 MYOG MYOD1 DMD
3 negative regulation of osteoblast proliferation GO:0033689 9.46 MIR9-1 MIR675
4 myotube differentiation GO:0014902 9.43 MYOG MYOD1
5 positive regulation of skeletal muscle fiber development GO:0048743 9.4 MYOG MYOD1
6 skeletal muscle fiber development GO:0048741 9.33 RYR1 MYOG MYOD1
7 muscle cell fate commitment GO:0042693 9.32 MYOG MYOD1
8 myotube cell development GO:0014904 9.26 MYOD1 DMD
9 muscle organ development GO:0007517 9.26 UTRN MYOG MYOD1 DMD
10 response to denervation involved in regulation of muscle adaptation GO:0014894 8.8 UTRN MYOG DMD

Molecular functions related to Muscular Disease according to GeneCards Suite gene sharing:

(showing 2, show less)
# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR9-1 MIR675 MIR221 MIR199A1 MIR142
2 vinculin binding GO:0017166 8.96 UTRN DMD

Sources for Muscular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....